RECHERCHE
boerse.de
Europas erstes Finanzportal
Aktien-Ausblick
kostenlos, schon >150.000 Leser
boerse.de-Aktienbrief
kostenlos + unverbindlich
Börsendienste
kostenlos + unverbindlich kennenlernen
Leitfaden für Ihr Vermögen
einzigartiges Börsenwissen kostenlos
INVESTMENT
boerse.de-Gold (TMG0LD)
Responsible Gold!
boerse.de-Fonds - ohne Agio!
boerse.de-Aktienfonds
boerse.de-Weltfonds
boerse.de-Technologiefonds
boerse.de-DividendenfondsNEU
boerse.de-Indizes
BCDI -
Das Original!
BCDI
USA
BCDI Deutschland
myChampionsPREMIUM
ab 500.000 Euro
myChampions100
Aktion: Ab 50.000 Euro
ÜBER UNS
SOUTH SAN FRANCISCO, Calif. –
Veracyte,
Inc. (Nasdaq: VCYT) today announced that members of its management
team will be participating in two upcoming investor conferences.
Executives from the company will be meeting with investors at the BTIG
MedTech, Life Science & Diagnostic Tools Conference 2019 on Wednesday,
February 27, 2019, in Snowbird, Utah. There will not be a webcasted
presentation.
Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the 8th Annual SVB Leerink Global Healthcare Conference in New York City on Friday, March 1, 2019 at 9:00 a.m. EST. A live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.
About Veracyte
Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that improves patient care by providing trustworthy and actionable answers to challenging clinical questions. The company's products uniquely combine advanced genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward, informing both diagnosis and treatment decisions without the need for costly, risky surgeries that are often unnecessary. Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).
View source version on businesswire.com: https://www.businesswire.com/news/home/20190220005883/en/
Quelle: Business Wireboerse.de-Börsenzitat:
Bester Weg, einen Homerun zu erzielen: nicht wild drauflos schlagen, sondern auf einen guten Wurf warten.
Ich bin damit einverstanden, dass die TM Börsenverlag AG und die Schwestergesellschaft boerse.de Vermögensverwaltung GmbH
mir regelmäßig Informationen zu aktuellen Produkten und Dienstleistungen aus dem Finanzbereich,
sowie den kostenlosen Newsletter boerse.de-Aktien-Ausblick zuschickt. Meine Einwilligung kann ich
jederzeit gegenüber der TM Börsenverlag AG widerrufen.
Unsere Datenschutzerklärung finden Sie hier.